Review of Eight Pharmacoeconomic Studies of the Value of Biologic DMARDs Adalimumab, Etanercept, and Infliximab) in the Management of Rheumatoid Arthritis

BACKGROUND: Treatment options for the management of rheumatoid arthritis (RA) have expanded from the traditional disease-modifying antirheumatic drugs (DMARDs) to include the biologic DMARDs that inhibit tumor necrosis factoralpha (TNF-a). OBJECTIVES: To assess the medical literature for studies of...

Descripción completa

Detalles Bibliográficos
Autores principales: Doan, Quan V., Chiou, Chiun-Fang, Dubois, Robert W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2006
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437502/
https://www.ncbi.nlm.nih.gov/pubmed/16981801
http://dx.doi.org/10.18553/jmcp.2006.12.7.555

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437502/
https://www.ncbi.nlm.nih.gov/pubmed/16981801
http://dx.doi.org/10.18553/jmcp.2006.12.7.555

Ejemplares similares